A Phase II, Open-label, Single Arm Trial of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Feb 2018 Status changed from not yet recruiting to recruiting.
- 11 Jan 2018 Planned initiation date changed from 2 Jan 2018 to 1 Mar 2018.